共 90 条
[1]
Connolly SJ(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151
[2]
Ezekowitz MD(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med. 365 883-891
[3]
Yusuf S(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-992
[4]
Eikelboom J(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104
[5]
Oldgren J(2017)Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study BMJ 356 j510-55
[6]
Parekh A(2018)Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study J Intern Med 283 45-63
[7]
Patel MR(2018)Two-year follow up of patients treated with dabigatran for stroke prevention in atrial fibrillation: global registry on long-term antithrobotic treatement in patients with atrial fibrillation (GLORIA-AF) registry Am Heart J 198 55-2889
[8]
Mahaffey KW(2016)Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF Eur Heart J 37 2882-272
[9]
Garg J(2010)Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 263-1100
[10]
Pan G(2010)A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 1093-2870